Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.

Saber H, Del Valle P, Ricks TK, Leighton JK.

Regul Toxicol Pharmacol. 2017 Nov;90:144-152. doi: 10.1016/j.yrtph.2017.09.001. Epub 2017 Sep 5.

PMID:
28887049
2.

Successes and Challenges of PARP Inhibitors in Cancer Therapy.

Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R.

Front Oncol. 2015 Oct 14;5:222. doi: 10.3389/fonc.2015.00222. eCollection 2015. Review. No abstract available.

3.

FDA Approval: Blinatumomab.

Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, Mehrotra N, Ricks TK, Schmiel D, Song P, Zhao P, Zhou Q, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Sep 15;21(18):4035-9. doi: 10.1158/1078-0432.CCR-15-0612.

4.

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.

Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.

Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17. Review.

5.

Immunoglobulin E plays an immunoregulatory role in lupus.

Dema B, Charles N, Pellefigues C, Ricks TK, Suzuki R, Jiang C, Scheffel J, Hasni S, Hoffman V, Jablonski M, Sacré K, Gobert D, Papo T, Daugas E, Crampton S, Bolland S, Rivera J.

J Exp Med. 2014 Oct 20;211(11):2159-68. doi: 10.1084/jem.20140066. Epub 2014 Sep 29.

6.

Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis.

Dema B, Pellefigues C, Hasni S, Gault N, Jiang C, Ricks TK, Bonelli MM, Scheffel J, Sacré K, Jablonski M, Gobert D, Papo T, Daugas E, Illei G, Charles N, Rivera J.

PLoS One. 2014 Feb 28;9(2):e90424. doi: 10.1371/journal.pone.0090424. eCollection 2014.

7.

Kinetic scaffolding mediated by a phospholipase C-beta and Gq signaling complex.

Waldo GL, Ricks TK, Hicks SN, Cheever ML, Kawano T, Tsuboi K, Wang X, Montell C, Kozasa T, Sondek J, Harden TK.

Science. 2010 Nov 12;330(6006):974-80. doi: 10.1126/science.1193438. Epub 2010 Oct 21.

8.

Phosphorylation of protease-activated receptor-2 differentially regulates desensitization and internalization.

Ricks TK, Trejo J.

J Biol Chem. 2009 Dec 4;284(49):34444-57. doi: 10.1074/jbc.M109.048942. Epub 2009 Oct 8.

9.

Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer.

Arora P, Ricks TK, Trejo J.

J Cell Sci. 2007 Mar 15;120(Pt 6):921-8. Review.

10.

Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.

Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J.

Cancer Res. 2006 Jan 1;66(1):307-14.

Supplemental Content

Loading ...
Support Center